ASH Clinical News July 2017 V2 - Page 9

UP FRONT ASH Directions AML Matters Summit Continues Across U.S. AML Matters is a free educational program designed to provide guidance to health-care professionals on the optimal diagnosis and classification of acute myeloid leukemia, risk stratification, individualized treatment selection, assessment of treatment responses, monitoring for and mitigation of adverse events, and patient education regarding prognosis and treatment choices. This program is sponsored by the American Society of Hematology, American Society for Clinical Pathology, National Marrow Donor Program, Oncology Nursing Society, and The France Foundation. Upcoming dates and locations include: • Minneapolis, MN (July 28, 2017) • Durham, NC (October 20, 2017) • Philadelphia, PA (October 27, 2017) Visit for more information and to register. Minneapolis, MN Plan Ahead for ASH Meeting on Lymphoma Biology It’s not too soon to mark your calendar for the next ASH Meeting on Lymphoma Biology, taking place August 2-5, 2018, just out- side Washington, DC. This 4-day meeting offers a platform for the latest developments in lymphoma science, identifying challenges and establishing the highest priorities for investigation. The target audience for this meeting includes laboratory-based scien- tists, translational investigators, pharmaceutical scientists, and others interested in lymphoma science. For more information, visit Webinar Preview of the 2017 ASH Meeting on Hematologic Malignancies A panelist of experts, including Kenneth Anderson, MD (far right), discuss precision medicine. ASH President Participates in LLS Panel Discussion American Society of Hematology (ASH) President Kenneth Anderson, MD, partici- pated in an event organized by The Leukemia & Lymphoma Society (LLS) with other leading experts on blood cancers and health-care policy in Washington, DC, in early May to discuss the rising cost of cancer care, as well as advances in precision medicine and immunotherapy. In conjunction with the event, LLS issued its Report to the Nation: Leading the Way to Cancer Cures, a comprehensive overview of the major scientific, treatment, and policy advances of the last six decades that have affected patients with blood cancer. The panel discussion, titled, “Precision Medicine: Pursuing Novel Targeted Therapies and Immunotherapies to Fight Cancer,” featuring leukemia, lymphoma, and myeloma researchers and clinicians, discussed the potential of new scientific discoveries to change the model of cancer treatment. “Of course we’re going to cure cancer,” said Dr. Anderson. “There’s not even any question. The way it’s going to be done is by a team.” Source: Leukemia & Lymphoma Society news release, May 3, 2017. A special webinar series preview- ing the 2017 ASH Meeting on Hematologic Malignancies is avail- able for free streaming from ASH On Demand at Webinars. If you’re considering attending the meeting, watch this series to get a sense of the content that will be covered in person, September 8-9 in Chicago, Illinois. The meeting will feature top experts in the field, comprehensive clinical updates, the latest clinical research, and opportunities to interact with colleagues in a small-group setting. The core malignancies covered at the meeting include leukemia, lym- phoma, myelodysplastic syndromes, myeloma, and myeloproliferative neoplasms. For information visit The most recent webinar took place in May and featured a discus- sion on the state of myeloprolifera- tive neoplasms with Ruben Mesa, MD, Mayo Clinic, Phoenix, Arizona, and Jason Gotlib, MD, Stanford University, California. Call for Abstracts for 2017 ASH Annual Meeting The abstract submission site (hematology. org/Annual-Meeting/Abstracts) for the 59th ASH Annual Meeting is now open. ASH is accepting submissions across 65 scientific and clinical categories, spanning the entire field of hematology. The submission deadline is August 2 at 11:59 p.m. This year’s meeting will be held December 9-12 in Atlanta, Georgia. Registration and housing open July 19 at 11:00 a.m. for ASH members and August 9 at 11:00 a.m. for non-members. Visit Annual-Meeting for more information. ● ASH Clinical News 7